Education
About Us
Working with TipRanks
Follow Us
EGF Theramed Health (TSE:TMED)
:TMED
Top Page
EGF Theramed Health
(TMED)
Select Model
Select Model
Rating:19Underperform
Price Target:―
EGF Theramed Health's overall stock score is very low, primarily due to its severe financial challenges, including negative income, balance sheet instability, and poor cash flow management. Technical indicators suggest weak stock momentum, and valuation metrics are unappealing due to the company's ongoing losses. These factors collectively contribute to a high-risk profile for potential investors.
Positive Factors
Innovative Health Solutions
EGF Theramed Health's focus on genomic and regenerative therapies positions it well in the growing personalized healthcare market, offering potential for future revenue growth and competitive advantage through innovation.
Strategic Collaborations
Strategic partnerships for co-developing treatments can enhance product offerings and provide additional revenue streams, supporting long-term growth and innovation in the healthcare sector.
Product and Service Diversification
Diversified revenue streams from proprietary products and services reduce dependency on a single income source, potentially stabilizing earnings and supporting sustainable business operations.
Negative Factors
Financial Instability
The company's negative equity and cash flow issues indicate significant financial instability, which could hinder its ability to invest in growth opportunities and sustain operations long-term.
Zero Revenue Generation
The lack of revenue generation suggests operational challenges and an inability to monetize its offerings, posing a risk to financial health and long-term viability.
High Leverage
High leverage and negative equity increase financial risk, limiting flexibility and potentially leading to solvency issues if not addressed through strategic financial management.
EGF Theramed Health (TMED) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$813.17K
Dividend YieldN/A
Average Volume (3M)1.23K
Price to Earnings (P/E)―
Beta (1Y)0.42
Revenue GrowthN/A
EPS Growth-1188.37%
CountryCA
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,616,665
10 Day Avg. Volume1,800
30 Day Avg. Volume1,233
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.26
Price to Sales (P/S)0.00
P/FCF Ratio38.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
EGF Theramed Health Business Overview & Revenue Model
Company DescriptionEGF Theramed Health (TMED) is a healthcare company that operates in the biotechnology and wellness sectors. It focuses on developing and providing innovative health solutions, particularly in the areas of genomic medicine and regenerative health therapies. The company aims to enhance patient outcomes through cutting-edge treatments and personalized healthcare services.
How the Company Makes MoneyEGF Theramed Health (TMED) generates revenue through the development and commercialization of genomic and regenerative health therapies. Key revenue streams include the sale of proprietary health products and therapies, as well as offering specialized healthcare services. The company may also engage in partnerships with research institutions or other healthcare entities to co-develop new treatments, which can provide additional revenue through licensing agreements or joint ventures. Strategic collaborations and advancements in their product offerings contribute significantly to their earnings.
EGF Theramed Health Financial Statement Overview
Summary
EGF Theramed Health is experiencing severe financial difficulties, evidenced by zero revenue, ongoing losses, negative equity, and challenging cash flow management. The company faces significant risks due to high leverage and a lack of income generation, necessitating urgent strategic changes to improve financial stability.Income Statement
The company has consistently reported zero revenue over the past years, indicating a complete lack of income generation. Both EBIT and Net Income have remained negative, reflecting ongoing operational losses. The absence of revenue growth and persistent losses severely impact the financial health.10
Very Negative
Balance Sheet
The company exhibits a highly leveraged balance sheet with negative stockholders' equity, indicating insolvency. The debt-to-equity ratio is not meaningful due to negative equity. This suggests significant financial instability and high financial risk.5
Very Negative
Cash Flow
Free cash flow remains negative, although slightly improved in recent periods. Operating cash flow consistently trails net income, indicating cash management issues. The cash flow situation reflects ongoing financial strain, though there is some support from financing activities.15
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ― |
| EBITDA | -305.87K | -2.33M | -238.64K | -568.50K | -1.35M | -677.89K |
| Net Income | -318.23K | -3.21M | -269.25K | -623.00K | -1.69M | -968.71K |
Balance Sheet | ||||||
| Total Assets | 22.61K | 22.34K | 214.41K | 193.69K | 178.67K | 1.20M |
| Cash, Cash Equivalents and Short-Term Investments | 13.90K | 14.01K | 10.01K | 11.72K | 15.23K | 702.63K |
| Total Debt | 1.56M | 1.51M | 1.47M | 1.34M | 1.22M | 1.12M |
| Total Liabilities | 5.99M | 5.93M | 2.92M | 2.67M | 2.51M | 2.41M |
| Stockholders Equity | -4.57M | -4.52M | -1.34M | -1.14M | -1.02M | 91.48K |
Cash Flow | ||||||
| Free Cash Flow | -161.52K | 29.75K | -134.71K | -576.01K | -993.42K | -783.76K |
| Operating Cash Flow | -161.52K | 29.75K | -134.71K | -576.01K | -993.42K | -783.76K |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 410.43K |
| Financing Cash Flow | -21.75K | -25.75K | 133.00K | 572.50K | 306.02K | 712.20K |
EGF Theramed Health Technical Analysis
Negative
0.07
Price Trends
0.10
Negative
0.09
Negative
0.09
Negative
Market Momentum
>-0.01
Positive
6.88
Positive
>-0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:TMED, the sentiment is Negative. The current price of 0.07 is below the 20-day moving average (MA) of 0.08, below the 50-day MA of 0.10, and below the 200-day MA of 0.09, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 6.88 is Positive, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:TMED.
EGF Theramed Health Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
42 Neutral | C$866.33K | -0.23 | ― | ― | ― | ― | |
39 Underperform | C$619.91K | -2.68 | -40.64% | ― | -100.00% | 65.85% | |
33 Underperform | C$7.10M | -5.12 | ― | ― | ― | -67.11% | |
29 Underperform | C$8.99M | -1.94 | ― | ― | ― | 81.01% | |
19 Underperform | C$813.17K | -0.25 | ― | ― | ― | -1188.37% |
* Healthcare Sector Average
TSE:TMED
EGF Theramed Health
0.07
-0.08
-53.33%
TSE:NEWU
Newtopia
0.01
0.00
0.00%
TSE:NDAT
nDatalyze Corp
0.02
-0.06
-75.00%
TSE:KETA
TripSitter Clinic Ltd
0.06
0.04
200.00%
TSE:NARA
PanGenomic Health, Inc. Class A
0.64
0.48
300.00%
TSE:DMED
DiagnaMed Holdings Corp.
0.06
0.04
200.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.